ClinicalTrials.Veeva

Menu

Impact of Evolocumab in Cardiac Transplant Patients With CAV

University of Nebraska logo

University of Nebraska

Status and phase

Completed
Phase 2

Conditions

Heart Transplant

Treatments

Drug: Evolocumab

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03944577
0104-19-FB

Details and patient eligibility

About

Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowering low density lipoprotein (LDL) in patients who have not received a heart transplant. This drug works as a PCSK9-inhibitor. The primary objective of this study is to measure the impact of PCSK9-inhibitors on serum LDL in heart transplant patients with CAV after 12 weeks compared to baseline.

Full description

Heart transplant remains the treatment of choice for patients with advanced heart failure. Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of the donor heart, and limits long term survival after transplant. The pathophysiology of CAV is complex and involves smooth muscle proliferation, inflammatory infiltrates, and lipid deposition. To date, only statin therapy has reduced CAV-related mortality. PCSK9 inhibitors are a new lipid lowering therapy shown to reduce cardiovascular clinical events in patients with coronary artery disease. We hypothesize that PCSK9 inhibition via evolocumab will significantly lower low density lipoprotein (LDL) and be well-tolerated in transplant patients with CAV. This phase II, open label, single center trial with enroll up to 40 heart transplant patients with CAV for treatment with evolocumab for one year. The primary outcome will be percent change in LDL at 12 weeks. Secondary outcomes will include change in CAV progression, impact of evolocumab on immunosuppression regimens and transplant rejection, and change in serum lipids after 52 weeks. Results of this study are intended to provide safety data in heart transplant patients with CAV and assess secondary outcomes including CAV progression and impact on immunosuppression and transplant rejection.

Enrollment

26 patients

Sex

All

Ages

19 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Heart transplant patients 19-80 years of age
  • Coronary allograft vasculopathy grade 1 or 2 documented by left heart cardiac catheterization
  • Able to provide signed informed consent

Exclusion criteria

  • Cardiac allograft vasculopathy (CAV) grade 3
  • Rejection requiring IV therapy in the prior 3 months
  • Infection requiring IV therapy in the prior 3 months
  • Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal
  • Current or recent use of a PCSK9 inhibitor within the past 12 weeks
  • Organ transplant recipient other than heart
  • Renal dysfunction defined as glomerular filtration rate (GFR) < 20 ml/min
  • Known allergy to evolocumab or its components

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

26 participants in 1 patient group

Evolocumab
Experimental group
Description:
Patients who will receive the study drug.
Treatment:
Drug: Evolocumab

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems